SAM
DNLI icon

Sherman Asset Management’s Denali Therapeutics DNLI Stock Holding History

Sherman Asset Management’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-94
Closed -$1.28K – 150
2025
Q1 		$1.28K Hold
94
– – ﹤0.01% 148
2024
Q4 		$1.92K Buy
+94
New +$2.41K ﹤0.01% 147

Other funds holding DNLI

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Sherman Asset Management's DNLI Position: Q2 2025 in Review

Sherman Asset Management sold out of Denali Therapeutics (DNLI) in Q2 2025, closing a stake of 94 shares — an estimated $1.28K sold.

Sherman Asset Management first reported a position in DNLI in Q4 2024 and held it in 2 quarters. The position peaked at $1.92K in Q4 2024. 230 funds tracked by Wall St. Rank hold DNLI as of Q2 2025.

  • Sherman Asset Management reported no remaining Denali Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Sherman Asset Management sold 94 Denali Therapeutics shares in Q2 2025, an estimated $1.28K.
  • Sherman Asset Management first reported a position in Denali Therapeutics in Q4 2024 and held it in 2 quarters.
  • Sherman Asset Management's Denali Therapeutics position peaked at $1.92K in Q4 2024.
  • 230 funds tracked by Wall St. Rank held Denali Therapeutics as of Q2 2025.

Based on Sherman Asset Management's 13F filing for Q2 2025, filed 14 Aug 2025.